Literature DB >> 10737386

Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours.

S R Lin1, C H Hsu, J H Tsai, J Y Wang, T J Hsieh, C H Wu.   

Abstract

Our previous studies have shown that seven out of 15 patients with adrenocortical tumours contained K-ras gene mutation. In addition, the mutation type was a multiple-site mutation, and the hot spots were located at codons 15, 16, 18 and 31, which were different from those reported before (codons 12, 13 and 61). To understand whether the mutation hot spots in human adrenocortical tumours were associated with activation of K-Ras oncogene and the alterations of its biocharacteristics, mutant K-Ras genes were cloned from tumour tissues and then constructed with expression vector pBKCMV. Mutant K-Ras genes were expressed at high levels in Escherichia coli and the resultant K-Ras proteins were shown to be functional with respect to their well-known specific, high-affinity, GDP/GTP binding. The purified K-Ras protein from E. coli were then measured for their intrinsic GTPase activity and the GTPase activity in the presence of GTPase-activating protein for Ras. The results showed that the wild-type cellular K-Ras protein (p21BN) exhibits about ten times higher intrinsic GTPase activity than the activated protein (p21BM3) encoded by mutant K-Ras gene, which mutated at codon 60. With regards to the codon 15, 16, 18 and 31 mutant K-Ras proteins (p21BM2), the GTPase activity in the presence of GAP is much lower than that of the normal K-Ras protein, whereas the intrinsic GTPase activity is nearly the same as that of the normal K-Ras protein. These results indicated that mutations at these hot spots of K-Ras gene were indeed activated K-Ras oncogene in adrenocortical tumours; however, their association with tumors needs further experiments to prove.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737386      PMCID: PMC2374427          DOI: 10.1054/bjoc.1999.1039

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

1.  Ras binding to a C-terminal region of GAP.

Authors:  D P Molloy; D Owen; R J Grand
Journal:  FEBS Lett       Date:  1995-07-17       Impact factor: 4.124

2.  Developmentally-regulated expression of murine K-ras isoforms.

Authors:  S Pells; M Divjak; P Romanowski; H Impey; N J Hawkins; A R Clarke; M L Hooper; D J Williamson
Journal:  Oncogene       Date:  1997-10-09       Impact factor: 9.867

3.  The structural basis of the activation of Ras by Sos.

Authors:  P A Boriack-Sjodin; S M Margarit; D Bar-Sagi; J Kuriyan
Journal:  Nature       Date:  1998-07-23       Impact factor: 49.962

4.  JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone.

Authors:  L A Winston; T Hunter
Journal:  J Biol Chem       Date:  1995-12-29       Impact factor: 5.157

Review 5.  Guanine nucleotide exchange factors: activators of Ras superfamily proteins.

Authors:  A F Overbeck; T R Brtva; A D Cox; S M Graham; S Y Huff; R Khosravi-Far; L A Quilliam; P A Solski; C J Der
Journal:  Mol Reprod Dev       Date:  1995-12       Impact factor: 2.609

6.  The role of Gln61 and Glu63 of Ras GTPases in their activation by NF1 and Ras GAP.

Authors:  M S Nur-E-Kamal; H Maruta
Journal:  Mol Biol Cell       Date:  1992-12       Impact factor: 4.138

7.  Developmental regulation and neuronal expression of the mRNA of rat n-chimaerin, a p21rac GAP:cDNA sequence.

Authors:  H H Lim; G J Michael; P Smith; L Lim; C Hall
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

8.  Mutagenesis of the H-ras p21 at glycine-60 residue disrupts GTP-induced conformational change.

Authors:  Y J Sung; M Carter; J M Zhong; Y W Hwang
Journal:  Biochemistry       Date:  1995-03-14       Impact factor: 3.162

9.  Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Is there preference among K-ras mutants for malignant progression?

Authors:  N Yamashita; T Minamoto; A Ochiai; M Onda; H Esumi
Journal:  Cancer       Date:  1995-03-15       Impact factor: 6.860

10.  Residues crucial for Ras interaction with GDP-GTP exchangers.

Authors:  M Segal; B M Willumsen; A Levitzki
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

View more
  3 in total

1.  Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.

Authors:  Ming-Yii Huang; Hsueh-Chiao Liu; Li-Chen Yen; Jia-Yuan Chang; Jian-Jhang Huang; Jaw-Yuan Wang; Shiu-Ru Lin
Journal:  Tumour Biol       Date:  2014-06-27

2.  Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway.

Authors:  C-H Wu; Y-F Chen; J-Y Wang; M-C Hsieh; C-S Yeh; S-T Lian; S-J Shin; S-R Lin
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

3.  Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.

Authors:  John M Ketcham; Jacob Haling; Shilpi Khare; Vickie Bowcut; David M Briere; Aaron C Burns; Robin J Gunn; Anthony Ivetac; Jon Kuehler; Svitlana Kulyk; Jade Laguer; J David Lawson; Krystal Moya; Natalie Nguyen; Lisa Rahbaek; Barbara Saechao; Christopher R Smith; Niranjan Sudhakar; Nicole C Thomas; Laura Vegar; Darin Vanderpool; Xiaolun Wang; Larry Yan; Peter Olson; James G Christensen; Matthew A Marx
Journal:  J Med Chem       Date:  2022-07-14       Impact factor: 8.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.